Form 4: Director John Kozarich Executes LGND Stock Sales
Statement of Changes in Beneficial Ownership
Director John W. Kozarich exercised stock options and sold shares of Ligand Pharmaceuticals under a 10b5-1 trading plan.
Summary
- Director John W. Kozarich exercised options for 2,034 shares of common stock at an exercise price of $69.51.
- The director sold a total of 2,502 shares of common stock between May 1, 2026, and May 13, 2026.
- Sales were executed at prices ranging from $223.50 to $234.09 per share.
- All transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on March 7, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent routine portfolio management by a director.
Positives
- The director continues to maintain a significant beneficial ownership of 41,786 shares following the transactions.
Negatives
- The director reduced their total beneficial ownership position through the sale of 2,502 shares.
Risks
- Future sales by insiders under 10b5-1 plans may continue to impact the total number of shares held by directors.
Future Outlook
No specific forward-looking guidance provided; transactions were pre-planned under a 10b5-1 trading arrangement.
Industry Context
StockSavvy.ai notes that insider selling under 10b5-1 plans is a standard practice for liquidity and diversification among biotech executives and directors, and does not necessarily reflect a change in sentiment regarding the company's long-term prospects.
Comparison to Industry Standards
- The use of 10b5-1 plans is a standard corporate governance practice to avoid potential conflicts of interest regarding material non-public information.
- The exercise and sale of options nearing expiration is consistent with typical executive compensation management.
Stakeholder Impact
- Minimal impact expected as the transactions were executed under a pre-established trading plan.
Next Steps
- No further actions indicated beyond continued compliance with SEC reporting requirements.
Key Dates
| Date | Description |
|---|---|
| 2025-03-07 | Date the Rule 10b5-1 trading plan was adopted. |
| 2026-05-01 | Initial date of reported stock sales. |
| 2026-05-12 | Date of option exercise and subsequent sale. |
| 2026-05-13 | Date of final reported option exercise and sale. |
| 2026-05-14 | Date of filing. |
| 2026-05-23 | Expiration date of the exercised stock options. |
Keywords
Ligand Pharmaceuticals, LGND, Insider Trading, Form 4, Stock Options, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.